Loading…
Reported covered position: COUNSEL/SENATE
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2022 · fourth_quarter · Q4
-Implementation of the Orphan Drug Act of 1938 (Pub. L. No. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies - FDA User Fee Reauthorization Act of 2022, P.L. 117-180, reauthorization of FDA user fees, and Consolidated Appropriations Act, FY2023, P.L. 117-328
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2022 · fourth_quarter · 4T
Source: Senate LDA
| CUBIST PHARMACEUTICALS |
| 38 |
| 2006–2015 |
| ELI LILLY AND COMPANY | 28 | 2006–2013 |
| ABBOTT LABORATORIES | 26 | 2007–2012 |
| ASTRAZENECA PHARMACEUTICALS LP | 23 | 2005–2011 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 21 | 2003–2010 |
| BAXTER | 19 | 2014–2018 |
| BLUEBIRD BIO | 18 | 2016–2020 |
| PFIZER, INC. | 18 | 2006–2010 |
| PHARMATHENE, INC. | 18 | 2005–2010 |
| EDITAS MEDICINES, INC. | 17 | 2016–2020 |
| SUSAN G KOMEN FOR THE CURE | 17 | 2007–2012 |
| BIOTECHNOLOGY INDUSTRY ORGANIZATION | 16 | 2006–2010 |
| MERCK | 16 | 2003–2010 |
| OREXIGEN THERAPEUTICS, INC. | 16 | 2011–2014 |
| PANFLU LLC | 16 | 2007–2008 |
| MEDIMMUNE INC | 15 | 2007–2010 |
| ADAMAS PHARMACEUTICALS | 14 | 2008–2010 |
| GENENTECH INC | 14 | 2007–2009 |
| BECTON DICKINSON AND COMPANY | 13 | 2007–2010 |
| BRISTOL-MYERS SQUIBB | 12 | 2007–2010 |
| WAVE LIFE SCIENCES | 12 | 2020–2022 |
| BIOGEN IDEC INC. | 11 | 2004–2008 |
| NANOINK INC | 11 | 2007–2009 |
| SANOFI-AVENTIS U.S. INC. | 10 | 2007–2009 |
| ALEXION PHARMACEUTICALS, INC. | 9 | 2008–2010 |
| MICROSOFT CORPORATION | 9 | 2009–2010 |
| AMERICAN ORTHOTIC & PROSTHETIC ASSOCIATION | 8 | 2009–2010 |
| NATIONAL VENTURE CAPITAL ASSOCIATION | 8 | 2006–2015 |
| AMERICAN CAPITAL GROUP | 7 | 2005–2007 |
| CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND | 7 | 2010–2011 |
| CHIMERIX, INC. | 7 | 2012–2013 |
| INTUITIVE SURGICAL, INC. | 7 | 2013–2014 |
| INVERNESS MEDICAL INNOVATIONS | 7 | 2009 |
| ADVANCED CELL TECHNOLOGY | 6 | 2010–2011 |
| Medtronic, Inc. | 6 | 2011–2012 |
| CELGENE CORPORATION | 5 | 2010–2011 |
| CELL THERAPEUTICS INC | 5 | 2003–2004 |
| SCHOLASTIC | 5 | 2003–2006 |
| SPECTRUM PHARMACEUTICALS | 5 | 2011 |
| TONIX PHARMACEUTICALS | 5 | 2019–2020 |
| XDX INC | 5 | 2006–2010 |
| CAMBRIDGE HEART, INC. | 4 | 2004–2005 |
| GLAXOSMITHKLINE | 4 | 2009 |
| NOVARTIS | 4 | 2003–2004 |
| NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 4 | 2006–2007 |
| ORGANOGENESIS INC. | 4 | 2004–2005 |
| PHARMAJET | 4 | 2012 |
| BINX HEALTH | 3 | 2021 |
| CHIRON CORP | 3 | 2003–2004 |
| EMPI | 3 | 2003–2004 |
| GUILFORD PHARMACEUTICALS | 3 | 2003–2004 |
| HUMAN RIGHTS CAMPAIGN | 3 | 2006 |
| JOHNSON AND JOHNSON SERVICES, INC. | 3 | 2011 |
| KLEINER PERKINS CAUFIELD & BYERS | 3 | 2006 |
| MEDYTOX | 3 | 2018 |
| PARTNERS HEALTHCARE SYSTEM | 3 | 2011 |
| QLT | 3 | 2003–2004 |
| SHATTERPROOF | 3 | 2016 |
| T2 BIOSYSTEMS | 3 | 2022 |
| THERAVANCE BIOPHARMA | 3 | 2021 |
| ACADEMY OF MOLECULAR IMAGING | 2 | 2003–2005 |
| IMMUNEREGEN BIOSCIENCES INC | 2 | 2006–2007 |
| INTL ONCOLOGY NETWORK | 2 | 2004–2005 |
| RESPIRONICS INC | 2 | 2006 |
| TELADOC INC | 2 | 2012 |
| TRIUS THERAPEUTICS | 2 | 2013 |
| ALVEO TECHNOLOGIES | 1 | 2020 |
| BIOGEN | 1 | 2003 |
| MA ASSN OF 766 APPROVED PRIVATE SCHOOLS | 1 | 2003 |
| NEWBURY COLLEGE | 1 | 2003 |
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Protecting Our Communities from Gang Violence Act of 2018
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Protecting Medicare from Executive Action Act of 2017
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Medicare Part B and D payment for drugs -Issues relating to IPAB in S. 251 "Protecting Medicare from Executive Action of 2017" -Issues related to the repeal of the non-interference clause in Part D
Protecting Medicare from Executive Action Act of 2017
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Medicare Part B and D payment for drugs -Issues relating to IPAB in S. 251 "Protecting Medicare from Executive Action of 2017" -Issues related to the repeal of the non-interference clause in Part D
Veterinary Medicine Loan Repayment Program Enhancement Act
Client: BLUEBIRD BIO · Firm: FOLEY HOAG LLP
-Federal funding and regulation of innovative gene therapy technologies -H.R. 2430 and S. 932, FDA Reauthorizaiton Act -H.R. 1268 American Health Care Act and S. ___ Better Care Reconciliation Act
Veterinary Medicine Loan Repayment Program Enhancement Act
Client: BLUEBIRD BIO · Firm: FOLEY HOAG LLP
-Federal funding and regulation of innovative gene therapy technologies -H.R. 2430 and S. 932, FDA Reauthorization Act -H.R. 1268 American Health Care Act and S. ___ Better Care Reconciliation Act -S.2013 Trickett Wendler Right to Try Act of 2017.
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
American Health Care Act of 2017
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program.
Coverage of pharmaceuticals, cost-sharing, and other access issues, HR 2430 and S.934, FDA Reauthorization Act; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
Ryn White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV testing, screening, and linkage to care programs; HR 2430 and S.934, FDA Reauthorization Act. Federal program coverage; access and reimbursement issues for Hep C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing, and other access issues; Implementation of Pub. L. No. 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Ryn White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV testing, screening, and linkage to care programs; HR 2430 and S.934, FDA Reauthorization Act. Federal program coverage; access and reimbursement issues for Hep C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing, and other access issues; Implementation of Pub. L. No. 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255). -S.2013 Trickett Wendler Right to Try Act of 2017. -H.R. 2430 and S. 932, FDA Reauthorization Act. -Issues related to Zika vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
Coverage of pharmaceuticals, cost-sharing, and other access issues, HR 2430 and S.934, FDA Reauthorization Act; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program.
-Federal funding and regulation of innovative gene therapy technologies -H.R. 2430 and S. 932, FDA Reauthorizaiton Act -H.R. 1268 American Health Care Act and S. ___ Better Care Reconciliation Act
FDA Reauthorization Act of 2017
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
-Federal funding and regulation of innovative gene therapy technologies -H.R. 2430 and S. 932, FDA Reauthorization Act -H.R. 1268 American Health Care Act and S. ___ Better Care Reconciliation Act -S.2013 Trickett Wendler Right to Try Act of 2017.
Biological Implant Tracking and Veteran Safety Act of 2017
Client: BAXTER · Firm: FOLEY HOAG LLP
-End stage renal disease payment for home dialysis. -340B Drug Pricing Program. -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -CONNECT for Health Act of 2017 - Discussion Draft. - H.R. 28: Biological Implant Tracking and Veteran Safety Act of 2017.
Biological Implant Tracking and Veteran Safety Act of 2017
Client: BAXTER · Firm: FOLEY HOAG LLP
-End stage renal disease payment for home dialysis. -340B Drug Pricing Program. -21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -CONNECT for Health Act of 2017 - Discussion Draft - H.R. 28: Biological Implant Tracking and Veteran Safety Act of 2017
-Federal funding and regulation of innovative gene therapy technologies -H.R. 2430 and S. 932, FDA Reauthorization Act -H.R. 1268 American Health Care Act and S. ___ Better Care Reconciliation Act -S.2013 Trickett Wendler Right to Try Act of 2017.
Portfolio Lending and Mortgage Access Act
Client: SANOFI US SERVICES INC · Firm: FOLEY HOAG LLP
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255). -S.2013 Trickett Wendler Right to Try Act of 2017. -H.R. 2430 and S. 932, FDA Reauthorization Act. -Issues related to Zika vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: BAXTER · Firm: FOLEY HOAG LLP
-End stage renal disease payment for home dialysis. -340B Drug Pricing Program. -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -S. 870: Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: BAXTER · Firm: FOLEY HOAG LLP
-End-stage renal disease payment for home dialysis. -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -S. 870: Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
-Federal funding and regulation of innovative gene therapy technologies -H.R. 2430 and S. 932, FDA Reauthorizaiton Act -H.R. 1268 American Health Care Act and S. ___ Better Care Reconciliation Act
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255). -S.2013 Trickett Wendler Right to Try Act of 2017. -H.R. 2430 and S. 932, FDA Reauthorization Act. -Issues related to Zika vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
-Federal funding and regulation of innovative gene therapy technologies -H.R. 2430 and S. 932, FDA Reauthorization Act -H.R. 1268 American Health Care Act and S. ___ Better Care Reconciliation Act -S.2013 Trickett Wendler Right to Try Act of 2017.
Ryn White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV testing, screening, and linkage to care programs; HR 2430 and S.934, FDA Reauthorization Act. Federal program coverage; access and reimbursement issues for Hep C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing, and other access issues; Implementation of Pub. L. No. 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program.
Coverage of pharmaceuticals, cost-sharing, and other access issues, HR 2430 and S.934, FDA Reauthorization Act; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Veterans Pain Management Improvement Act
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Implementation of 21st Century Cures Act.
America's Red Rock Wilderness Act
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Implementation of 21st Century Cures Act.
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Regulation of molecular diagnostics. -H.R. 6 - 21st Century Cures (P.L. 114-255).
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255). -S.2013 Trickett Wendler Right to Try Act of 2017. -H.R. 2430 and S. 932, FDA Reauthorization Act. -Issues related to Zika vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
Ryn White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV testing, screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Federal program coverage; access and reimbursement issues for Hep C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing, and other access issues; Implementation of Pub. L. No. 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Advancing Hope Act of 2016
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
Advancing Hope Act of 2016
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
-Implementation of Orphan Drug Act and orphan drug development. -21st Century Cures Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -ACA Implementation -Reauthorization of Prescription Drug User Fee Act. -Re-authorization of the pediatric rare disease priority review voucher.
Advancing Hope Act of 2016
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Implementation of 21st Century Cures Act.
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Coverage of pharmaceuticals, cost-sharing, and other access issues, H.R. 21st Century Cures Act; Implementation of Pub. L. No. 114-1448, the ACA; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B. S. 3056: CREATES Act of 2016.
Comprehensive Addiction and Recovery Act of 2016
Client: GILEAD SCIENCES INC · Firm: FOLEY HOAG LLP
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Comprehensive Addiction and Recovery Act of 2016
Client: GILEAD SCIENCES INC · Firm: FOLEY HOAG LLP
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Historic Downtown Preservation and Access Act
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
-Implementation of Orphan Drug Act and orphan drug development. -HR 2430 and S.932, FDA Reauthorization Act. -Senate legislation on biomedical innovation. -S. 1878 Advancing Hope Act of 2016. -Pending health care legislation and potential impact on the biopharmaceutical industry. -HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act. -Reauthorization of Prescription Drug User Fee Act. -Implementation of 21st Century Cures Act.
Food and Drug Administration Safety Over Sequestration Act of 2015
Client: MCNEIL CONSUMER HEALTHCARE LLC · Firm: FOLEY HOAG LLP
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
Food and Drug Administration Safety Over Sequestration Act of 2015
Client: MCNEIL CONSUMER HEALTHCARE LLC · Firm: FOLEY HOAG LLP
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
Food and Drug Administration Safety Over Sequestration Act of 2015
Client: MCNEIL CONSUMER HEALTHCARE LLC · Firm: FOLEY HOAG LLP
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
Food and Drug Administration Safety Over Sequestration Act of 2015
Client: MCNEIL CONSUMER HEALTHCARE LLC · Firm: FOLEY HOAG LLP
- HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
- HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
DXM Abuse Prevention Act of 2015
Client: MCNEIL CONSUMER HEALTHCARE LLC · Firm: FOLEY HOAG LLP
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
DXM Abuse Prevention Act of 2015
Client: MCNEIL CONSUMER HEALTHCARE LLC · Firm: FOLEY HOAG LLP
- HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
DXM Abuse Prevention Act of 2015
Client: MCNEIL CONSUMER HEALTHCARE LLC · Firm: FOLEY HOAG LLP
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
DXM Abuse Prevention Act of 2015
Client: MCNEIL CONSUMER HEALTHCARE LLC · Firm: FOLEY HOAG LLP
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
- Federal funding and regulation of innovative gene therapy technologies. - H.R. 6, H.R. 35 - 21st Century Cures (P.L. 114-255).
- HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 - CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.
Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Century Cures Initiative;Senate biomedical counterpart to H.R. 6.
Ryan White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV testing, screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Federal program coverage; access and reimbursement issues for Hepatitis C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing and other access issues; Implementation of Public Law No: 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Century Cures Initiative;Senate biomedical counterpart to H.R. 6.
Regulation of molecular diagnostics. H.R. 6 - 21st Century Cures Act (P.L. 114-255).
- Federal funding and regulation of innovative gene therapy technologies. - H.R. 6, H.R. 35 - 21st Century Cures (P.L. 114-255).
21st Century Cures Act
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
Implementation of Orphan Drug Act and orphan drug development. H.R. 6, 21st Century Cures Act. Senate legislation on biomedical innovation.
21st Century Cures Act
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
Implementation of Orphan Drug Act and orphan drug development. H.R. 6 - 21st Century Cures Act. Senate legislation on biomedical innovation. S. 1878 "Advancing Hope Act of 2016" Pending healthcare legislation and potential impact on the biopharmaceutical industry Affordable Care Act implementation Re-authorization of Prescription Drug User Fee Act (PDUFA) Re-authorization of the pediatric rare disease priority review voucher
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) Pub.L. 112-144). H.R. 6, 21st Century Cures Act, and Senate innovation legislation Public-private education on OTC drug safety in relation to opioid addiction epidemic.
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
-Federal funding and regulation of innovative gene therapy technologies. -H.R. 6: 21st Century Cures (P.L. 114-255).
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
Coverage of pharmaceuticals, cost-sharing and other access issues; H.R. 6 - 21st Century Cures Act; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid and Affordable Care Act implementation; FDA issues and 340B. S. 3056: CREATES Act of 2016.
21st Century Cures Act
Client: HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) · Firm: FOLEY HOAG LLP
Implementation of Orphan Drug Act and orphan drug development. H.R. 6, 21st Century Cures Act. Senate legislation on biomedical innovation. Pending healthcare legislation and potential impact on the biopharmaceutical industry Affordable Care Act implementation Reauthorization of Prescription Drug User Fee Act (PDUFA)
Regulation of molecular diagnostics. House Committee on Energy & Commerce 21st Century Cures Initiative;Senate biomedical counterpart to H.R. 6.
- Implementation of the Affordable Care Act of 2010 (P.L. 111-148). - Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). - Implementation of Orphan Drug Act of 1983 (P.L 97-414) and orphan drug development. - H.R. 6 - 21st Century Cures (P.L. 114-255).
Personal Care Products Safety Act
Client: MCNEIL CONSUMER HEALTHCARE LLC · Firm: FOLEY HOAG LLP
- H.R. 1078, Food and Drug Administration Safety Over Sequestration Act of 2015, regarding all provisions. - H.R. 6 - 21st Century Cures Act (P.L. 114-255), regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related Fairness to Contact Lens Consumers Act (P.L. 108-164) and related FTC Contact Lens Rule. - H.R. 3250 - DXM Abuse Prevention Act of 2015, regarding all provisions. - S. 2994 - DXM Abuse Prevention Act of 2016, regarding all provisions. - S. 1014 - Personal Care Products Safety Act of 2015, regarding all provisions. - S. 277 - Contact lens Consumer Health Protection Act of 2016, regarding all provisions. - S 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act, regarding all provisions. - H.R. 2858 - Humane Cosmetics Act, regarding all provisions.
Personal Care Products Safety Act
Client: MCNEIL CONSUMER HEALTHCARE LLC · Firm: FOLEY HOAG LLP
- HR 1078, "Food and Drug Administration Safety Over Sequestration Act of 2015", regarding all provisions. - HR 6, "21st Century Cures Act", regarding all provisions. - Issues relating to cosmetic regulatory reform. - Issues related to pseudoephedrine. - Issues related to Pub.L. 108-164, "Fairness to Contact Lens Consumers Act" (FCLCA) and related FTC Contact Lens Rule. - H.R. 3250, "DXM Abuse Prevention Act of 2015", regarding all provisions. - S. 2994, "DXM Abuse Prevention Act of 2016", regarding all provisions. - S. 1014, "Personal Care Products Safety Act", regarding all provisions. - S. 277, "Contact lens Consumer Health Protection Act of 2016", regarding all provisions. - S 697, "Frank R. Lautenberg Chemical Safety for the 21st Century Act", regarding all provisions. - HR 2858, "Humane Cosmetics Act", regarding all provisions.
- FDA User Fee Reauthorization Act of 2022, P.L. 117-180, reauthorization of FDA user fees, and Consolidated Appropriations Act, FY2023, P.L. 117-328 -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T2 BIOSYSTEMS via FOLEY HOAG LLP
2022 · fourth_quarter · Q4
-BARDA funding for advanced diagnostics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T2 BIOSYSTEMS via FOLEY HOAG LLP
2022 · third_quarter · Q3
-BARDA funding for advanced diagnostics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T2 BIOSYSTEMS via FOLEY HOAG LLP
2022 · third_quarter · RR
-BARDA funding for advanced diagnostics.
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2022 · third_quarter · Q3
-Implementation of the Orphan Drug Act of 1938 (Pub. L. No. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies -H.R.7667, S.4348, reauthorization of FDA user fees
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2022 · third_quarter · Q3
-H.R.7667, S.4348, reauthorization of FDA user fees -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2022 · second_quarter · Q2
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Issues relating to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2022 · second_quarter · Q2
-Implementation of the Orphan Drug Act of 1938 (Pub. L. No. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies -Issues relating to the Prescription Drug User Fee Act (PDUFA VII), Generic Drug User Fee Amendments (GDUFA III), and Biosimilar User Fee Act (BsUFA III)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2022 · first_quarter · Q1
-Implementation of the Orphan Drug Act of 1938 (Pub. L. No. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies -Reauthorization of the Prescription Drug User Fee Act (PDUFA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2022 · first_quarter · Q1
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Reauthorization of the Prescription Drug User Fee Act (PDUFA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2021 · fourth_quarter · Q4
-Implementation of the Orphan Drug Act of 1938 (Pub. L. No. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2021 · fourth_quarter · Q4
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BINX HEALTH via FOLEY HOAG LLP
2021 · third_quarter · Q3
-Issues relating to COVID-19 testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERAVANCE BIOPHARMA via FOLEY HOAG LLP
2021 · third_quarter · Q3
-Issues relating to COVID-19 therapeutics development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2021 · third_quarter · Q3
-Implementation of the Orphan Drug Act of 1938 (Pub. L. No. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2021 · third_quarter · Q3
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERAVANCE BIOPHARMA via FOLEY HOAG LLP
2021 · second_quarter · Q2
-Issues relating to COVID-19 therapeutics development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BINX HEALTH via FOLEY HOAG LLP
2021 · second_quarter · Q2
-Issues relating to COVID-19 testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2021 · second_quarter · Q2
-Implementation of the Orphan Drug Act of 1938 (Pub. L. No. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2021 · second_quarter · Q2
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BINX HEALTH via FOLEY HOAG LLP
2021 · second_quarter · RR
-Issues related to COVID-19 testing
THERAVANCE BIOPHARMA via FOLEY HOAG LLP
2021 · second_quarter · RR
-Issues relating to COVID-19 therapeutics development
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2021 · first_quarter · Q1
-Implementation of the Orphan Drug Act of 1938 (Pub. L. No. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2021 · first_quarter · Q1
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2020 · fourth_quarter · Q4
-Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2020 · fourth_quarter · Q4
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2020 · fourth_quarter · 4T
-Issues relating to gene therapy, value-based arrangements, and the Patient Affordability, Value and Efficacy (PAVE) Act. -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2020 · third_quarter · Q3
-Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2020 · third_quarter · Q3
-Issues relating to gene therapy, value-based arrangements, and the Patient Affordability, Value and Efficacy (PAVE) Act. -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2020 · third_quarter · Q3
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2020 · third_quarter · Q3
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255) -Regulation of medical surprise billing
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALVEO TECHNOLOGIES via FOLEY HOAG LLP
2020 · fourth_quarter · RR
-Testing related to COVID-19
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2020 · second_quarter · Q2
-Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAVE LIFE SCIENCES via FOLEY HOAG LLP
2020 · second_quarter · RR
-Implementation of the Orphan Drug Act of 1938 (Pub. L. No. 97-414) and orphan drug development -Federal funding and regulation of innovative genetic technologies
BLUEBIRD BIO via FOLEY HOAG LLP
2020 · second_quarter · Q2
-Issues relating to gene therapy, value-based arrangements, and the Patient Affordability, Value and Efficacy (PAVE) Act. -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2020 · second_quarter · Q2
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2020 · second_quarter · Q2
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255) -Regulation of medical surprise billing
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS via FOLEY HOAG LLP
2020 · first_quarter · Q1
-FDA implementation of expedited review pathways
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2020 · first_quarter · Q1
-Issues relating to gene therapy, value-based arrangements, and the Patient Affordability, Value and Efficacy (PAVE) Act. -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2020 · first_quarter · Q1
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2020 · first_quarter · Q1
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2020 · first_quarter · Q1
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255) -Regulation of medical surprise billing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2020 · first_quarter · Q1
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Issues related to the Pandemic and All Hazards Preparedness Innovation Act of 2019 -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to drug and insulin pricing
-Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
TONIX PHARMACEUTICALS via FOLEY HOAG LLP
2019 · fourth_quarter · Q4
-FDA implementation of expedited review pathways
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2019 · fourth_quarter · Q4
-Issues relating to gene therapy, value-based arrangements, and the Patient Affordability, Value and Efficacy (PAVE) Act. -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2019 · fourth_quarter · Q4
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2019 · fourth_quarter · Q4
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2019 · fourth_quarter · Q4
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255) -Regulation of medical surprise billing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2019 · fourth_quarter · Q4
-Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Issues related to the Pandemic and All Hazards Preparedness Innovation Act of 2019 -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to drug and insulin pricing
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2019 · third_quarter · Q3
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS via FOLEY HOAG LLP
2019 · third_quarter · Q3
-FDA implementation of expedited review pathways
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2019 · third_quarter · Q3
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2019 · third_quarter · Q3
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2019 · third_quarter · Q3
-Issues relating to gene therapy, value-based arrangements, and the Patient Affordability, Value and Efficacy (PAVE) Act. -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2019 · third_quarter · Q3
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Issues related to the Pandemic and All Hazards Preparedness Innovation Act of 2019 -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to drug and insulin pricing
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
TONIX PHARMACEUTICALS via FOLEY HOAG LLP
2019 · second_quarter · Q2
-FDA implementation of expedited review pathways
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2019 · second_quarter · Q2
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to drug and insulin pricing
-Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2019 · second_quarter · Q2
-Orphan Drug Tax Credit and Orphan Drug Development -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2019 · second_quarter · Q2
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2019 · second_quarter · Q2
-Issues relating to gene therapy, value-based arrangements, and the Patient Affordability, Value and Efficacy (PAVE) Act. -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2019 · second_quarter · Q2
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TONIX PHARMACEUTICALS via FOLEY HOAG LLP
2019 · second_quarter · RR
-FDA implementation of expedited review pathways.
BLUEBIRD BIO via FOLEY HOAG LLP
2019 · first_quarter · Q1
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2019 · first_quarter · Q1
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2019 · first_quarter · Q1
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2019 · first_quarter · Q1
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2019 · first_quarter · Q1
-Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2018 · fourth_quarter · Q4
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2018 · fourth_quarter · Q4
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2018 · fourth_quarter · Q4
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2018 · fourth_quarter · Q4
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2018 · fourth_quarter · Q4
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
2018 · third_quarter · 3@
-FDA regulation of biologicals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2018 · third_quarter · 3A
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2018 · third_quarter · Q3
-Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2018 · third_quarter · Q3
-General end-stage renal disease payment and reimbursement -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan -Implementation of Sec. 50302 of the Bipartisan Budget Act of 2018: Expanding Access To Home Dialysis Therapy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · RA
-Regulation of biological products.
2018 · second_quarter · RR
-Regulation of biological products.
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2018 · second_quarter · Q2
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2018 · second_quarter · Q2
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2018 · second_quarter · Q2
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2018 · second_quarter · 2A
-Medicare Part B and D payment for drugs -Issues related to the repeal of the non-interference clause in Part D
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2018 · second_quarter · Q2
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2018 · second_quarter · Q2
-End-stage renal disease payment for home dialysis -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan -Implementation of Sec. 50302 of the Bipartisan Budget Act of 2018: Expanding Access To Home Dialysis Therapy -Payment for new technologies in the End-Stage Renal Disease Prospective Payment System
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2018 · second_quarter · Q2
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152) -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
SANOFI US SERVICES INC via FOLEY HOAG LLP
2018 · first_quarter · Q1
-Medicare Part B and D payment for drugs -Issues relating to IPAB in S. 251 "Protecting Medicare from Executive Action of 2017" -Issues related to the repeal of the non-interference clause in Part D
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152) -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
COALITION FOR THE 21ST CENTURY via FOLEY HOAG LLP
2018 · first_quarter · Q1
-Regulation of molecular diagnostics -Implementation of 21st Century Cures (P.L. 114-255)
-Medicare payment and coding for clinical laboratory tests -Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2018 · first_quarter · Q1
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BLUEBIRD BIO via FOLEY HOAG LLP
2018 · first_quarter · Q1
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148) -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the 21st Century Cures Act (P.L. 114-255) -Implementation of the FDA Reauthorization Act (P.L. 115-52) -Federal funding and regulation of innovative gene therapy technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2018 · first_quarter · Q1
-Federal funding and regulation of innovative recombinant genetic technologies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2018 · first_quarter · Q1
-End-stage renal disease payment for home dialysis -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan -Implementation of Sec. 50302 of the Bipartisan Budget Act of 2018: Expanding Access To Home Dialysis Therapy -Payment for new technologies in the End-Stage Renal Disease Prospective Payment System
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER via FOLEY HOAG LLP
2017 · fourth_quarter · Q4
-End-stage renal disease payment for home dialysis. -Implementation of 21st Century Cures Legislation: Sec. 4013 - Telehealth Services in Medicare. -Implementation of 21st Century Cures Legislation: Sec. 17006 - Allowing ESRD Beneficiaries to Choose A Medicare Advantage Plan. -S. 870: Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HORIZON THERAPEUTICS USA (FORMERLY HORIZON PHARMA) via FOLEY HOAG LLP
2017 · fourth_quarter · Q4
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of the 21st Century Cures Act (P.L. 114-255). -Implementation of the FDA Reauthorization Act (P.L. 115-52).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via FOLEY HOAG LLP
2017 · fourth_quarter · Q4
-Medicare Part B payment for drugs.
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148). -Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152). -Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development. -Implementation of 21st Century Cures (P.L. 114-255). -Issues related to pandemic and seasonal influenza vaccine development. -Issues related to over-the-counter drug and cosmetic reform legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDITAS MEDICINES, INC. via FOLEY HOAG LLP
2017 · fourth_quarter · Q4
-Federal funding and regulation of innovative recombinant genetic technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of 21st Century Cures (P.L. 114-255) -Issues related to pandemic and seasonal influenza vaccine development -Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417) -Issues related to over-the-counter drug and cosmetic reform legislation -Issues related to Right to Try -Issues related to drug and insulin pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Medicare Part B and D payment for drugs -Issues relating to IPAB in S. 251 "Protecting Medicare from Executive Action of 2017" -Issues related to the repeal of the non-interference clause in Part D
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018" -Issues related to H.R. 1892 "Bipartisan Budget Act of 2018" -Issues related to National Institute of Health funding -Issues related to Biomedical Advanced Research and Development Authority
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE